Previous 10 | Next 10 |
Neovasc (NASDAQ: NVCN ): Q2 GAAP EPS of -$1.17 beats by $0.18 . Revenue of $0.44M (+7.3% Y/Y) misses by $0.23M . Shares -1.6% . Press Release More news on: Neovasc Inc., Earnings news and commentary, Healthcare stocks news, ,
NASDAQ, TSX: NVCN Recent Highlights Received Guidance from FDA to explore a potential Humanitarian Device Exemption Pathway for Neovasc Reducer™ (the "Reducer") for CCS class IV patients and to meet for another Sprint discussion Closed Private Placement of Convertible De...
Presentation Scheduled for 11:30 am Eastern Time on August 8 th NASDAQ, TSX: NVCN VANCOUVER , Aug. 5, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replace...
Conference Call Scheduled for 4:30 pm Eastern Time on August 7 th NASDAQ, TSX: NVCN VANCOUVER , Aug. 2, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve repla...
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency Canada NewsWire VANCOUVER, July 17, 2019 NASDAQ, TSX: NVCN VANCOUVER , July 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) ...
Immuron (NASDAQ: IMRN ) +134% on revenue surge . More news on: Immuron Limited, Neovasc Inc., Bio-Path Holdings, Inc., Stocks on the move, Read more ...
Pending U.S. Food and Drug Administration ("FDA") Humanitarian Use Device ("HUD") Classification and Approval as a HUD, Company Expects to Begin Commercializing Reducer in U.S. by Early 2020 A potential HUD Reducer designation for Canadian Cardiovascular Society ("CCS") Class IV...
Neovasc (NASDAQ: NVCN ) announces its U.S. regulatory approval plan for Neovasc Reducer, a stent-like device used to treat refractory angina (chest pain caused by inadequate blood flow to the heart). More news on: Neovasc Inc., Healthcare stocks news, Read more ...
Neovasc to Explore HDE Approval Pathway and Alternate Trial Designs for the Reducer Following Guidance from the FDA Canada NewsWire VANCOUVER, July 12, 2019 NASDAQ, TSX: NVCN VANCOUVER , July 12, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TS...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...
News, Short Squeeze, Breakout and More Instantly...
Neovasc Inc. (NASDAQ: NVCN) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.48% on the day to $29.23. Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. It...
VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Hi...
VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as d...